|
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 ALISO VIEJO, Calif.--(BUSINESS WIRE)--Feb 10, 2010 - AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
(BUSINESS WIRE) ----AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine), extending the...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
(BUSINESS WIRE) ----AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine), extending the...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
BusinessWire - AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine), extending the period...
|
|
|
AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA
AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine), extending the period of patent...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 Buzz up!Companies: Related Quotes {"s" : "avnr","k" : "c10,l10,p20,t10","o" : "","j" : ""} ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc! (NASDAQ: AVNR - News) today announced that...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
AVANIR Pharmaceuticals, Inc.( NASDAQ:AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine), extending the period of patent...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); ALISO VIEJO, Calif.- (Business Wire) AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine), extending the period of patent...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 ALISO VIEJO, Calif.--(BUSINESS WIRE)-- AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR - News) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for...
|
|
|
AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine), extending the period of patent...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia
AVANIR Pharmaceuticals, Inc.AVNR today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine), extending the period of patent protection in the...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia ...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
ALISO VIEJO, Calif.- (BUSINESS WIRE) - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine...
|
|
|
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
Provides Patent Protection for PBA Indication into 2025 ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its...
|
